A bumper harvest in stone medicine!

Recently, CSPC announced its 2020 results.
The annual revenue was 24.
942 billion yuan, a year-on-year increase of 12.
8%; the net profit was 5.
16 billion yuan, a year-on-year increase of 38.
9%, breaking the 5 billion mark
.
In the finished drug business, anti-tumor and cardiovascular drugs increased by 29.
0% and 61.
9%, respectively.
Innovative drug products achieved new successes, and the successful bidding of centralized procurement brought new sources of profit growth
.
At present, CSPC has 43 varieties (16 being the first), and 18 varieties have won the bidding for national sourcing
.
R&D expenses have increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%.
Currently, the group has about 300 research projects.
Small-molecule innovative drugs, large-molecule innovative drugs, and new formulations are working together.
Many new drugs are in the phase III clinical/marketing application stage
.

　　Net profit exceeded 5 billion! A bumper harvest of anti-tumor and cardiovascular drugs
2016-2020 CSPC Group's performance (unit: 100 million yuan) On March 15, CSPC announced its 2020 results.
The group's annual revenue was 24.
942 billion yuan, a year-on-year increase of 12.
8%; net Profit increased by 38.
9% to 5.
16 billion yuan, a significant jump from 2019
.
Among them, the revenue of patent medicine business was 20.
405 billion yuan, a year-on-year increase of 13.
8%; the revenue of antibiotics and other raw materials was 1.
373 billion yuan, a year-on-year increase of 30.
4%; the income of functional foods and other products was about 1.
306 billion yuan, a year-on-year increase of 9.
5%; the revenue of vitamin C raw materials was 1.
859 billion Yuan, a year-on-year decline of 3.
2%
.
The over-the-counter medicine business is the main driver of CSPC's performance growth
.
From the perspective of drug treatment, neurological disease products and anti-tumor products are the two pillars of CSPC's proprietary medicine business, with sales revenues of 7.
414 billion yuan and 6.
294 billion yuan respectively
.
The sales revenue of cardiovascular disease products and respiratory system disease products rose sharply, increasing by 61.
9% and 54.
4% year-on-year respectively
.
Innovative drug products continue to maintain rapid growth, and blockbuster products such as Enbipu, Duomexu, Jinyouli and Keaili once again created impressive sales results
.
Among them, Domesu increased by 41.
3%, Jinyouli increased by 37.
3%, Xuanning increased by 36.
8%, Enbipu increased by 17.
4%, and Keaili increased by 16.
4%
.
It is worth noting that volume procurement has become a new source of profit growth for CSPC
.
Among the 28 main products, 8 are nationally collected bid-winning products, including clopidogrel bisulfate tablets, amoxicillin capsules, azithromycin tablets, paclitaxel for injection (albumin-bound type), metformin hydrochloride tablets/sustained-release tablets, and Ruhast sodium chewable tablets, ticagrelor tablets and pramipexole hydrochloride tablets, of which 6 products have been approved for marketing in recent years
.
CSPC medicine business various therapeutic areas product sales
　　to win the blockbuster first imitation, over 43 varieties comment Pa screen
announcement shows that since 2020, CSPC total of 17 products have drug registration approval document, 14 products have clinical trials this document , 24 varieties passed the consistency evaluation of generic drugs
.
Just recently, CSPC's ceftriaxone sodium for injection passed the consistency evaluation, and the imitation of the 4 types of nintedanib ethanesulfonate soft capsules and entecavir tablets were approved and deemed to have been reviewed
.
Entecavir is a first-line drug for the treatment of hepatitis B, and nintedanib is a small molecule tyrosine kinase inhibitor and the world's first targeted drug approved for the treatment of idiopathic pulmonary fibrosis (IPF)
.
Since 2021, CSPC has been approved for marketing in three varieties in China, including esomeprazole magnesium enteric-coated capsules, entecavir tablets and nintedanib ethanesulfonate soft capsules
.
Among them, nintedanib ethanesulfonate soft capsule is the first domestic imitation, and esomeprazole magnesium enteric-coated capsule is the third domestically
.
Up to now, CSPC has passed/deemedly passed the consistency evaluation for 43 varieties (68 product specifications)
.
Among the 43 varieties, there are 15 systemic antibacterial drugs, 6 antitumor drugs, and 4 antithrombotic drugs and 4 diabetes drugs
.
CSPC passed/deemed passed consistency evaluation.
Source: Meinenet MED2.
0 Chinese drug review database.
From the review order, CSPC has 16 varieties that have been reviewed for the first time in China.
Glimepiride dispersible tablets 7, ranitidine hydrochloride capsules, cefadroxil tablets, tramadol hydrochloride tablets, nintedanib ethanesulfonate soft capsules, amoxicillin dispersible tablets, dasatinib tablets and other 7 varieties are temporarily reviewed exclusively
.
Among the four batches of drug procurement carried out by the state, CSPC has won the bid for a total of 18 varieties
.
Among them, 12 varieties have been approved and listed under the new registration classification, and the market is waiting to be developed.
The winning bid for centralized procurement will help to increase the volume quickly
.
The 　　research and development of the four batches of quarrying medicine group selections has
invested 2.
89 billion yuan! 49 innovative drugs were unveiled.

Recently, CSPC’s SKLB1028 capsules and SYHX1901 tablets have been approved for clinical trials one after another, and BPI-7711 capsules (EGFR-TKI) and Connoa’s BPI-7711 capsules (EGFR-TKI) have been introduced heavily.
CM310 (IL-4Rα monoclonal antibody)
.
The advancement and enrichment of the R&D pipeline has benefited from the company's large R&D expenditures
.
In the past three years, CSPC has continued to increase investment in research and development, and the compound growth rate of research and development expenses has reached 46.
7%
.
For the whole year of 2020, CSPC's research and development expenses have increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%
.
2018-2020 R&D expenses of CSPC (unit: 100 million yuan) CSPC focuses on the discovery of small molecule targeted drugs, nano drugs, monoclonal antibody drugs, double antibody drugs, antibody conjugate drugs and biological drugs in the immune field.
Research and development
.
There are currently about 300 research projects, including more than 40 small molecule innovative drugs, more than 40 macromolecule innovative drugs, and more than 20 new preparations, mainly focusing on tumors, autoimmunity, neuropsychiatry, digestion and metabolism, cardiovascular and cerebrovascular systems And anti-infection and other six treatment areas
.
Among the more than 40 innovative small molecule drugs under development, 18 are in the clinical research phase, 4 of which are in the phase III/registered clinical phase, and more than 20 are in the preclinical research phase
.
Duvelisib has submitted a marketing application, and SKLB1028, BPI-7711, butylphthalide soft capsules, and DBPR108 are all in the phase III clinical research phase
.
CSPC is mainly researching more than 40 small-molecule innovative drugs.
Among the more than 40 large-molecule innovative drugs under research, 16 are in the clinical research stage, of which 5 are registered for clinical trials, and more than 20 are in the preclinical research stage
.
Anti-RANKL monoclonal antibody (JMT103), anti-EGFR monoclonal antibody (JMT101), anti-PD-1 monoclonal antibody (SYSA1802), omalizumab biosimilars, etc.
are all in the phase III clinical research phase.
JMT103 is expected to be in 2022 -Listed in 2023
.
CSPC is mainly researching more than 20 innovative new-type drugs for large molecules, 3 of which are pending approval for production, 10 are undergoing clinical research, and more than 10 are in the preclinical research stage
.
Among them, amphotericin B liposomes have been submitted for marketing applications, and irinotecan liposomes will be submitted for marketing applications in the near future
.
Amphotericin B nanocomplex and mitoxantrone liposomes have been reported to NDA and received priority review, and are expected to be approved for marketing this year
.
CSPC is mainly researching new preparations.
CSPC stated that it will adhere to innovative R&D strategies, continue to increase R&D investment, and maintain R&D expenses as a percentage of sales revenue at more than 10%.
Every year, new products and major products are approved for listing.

.
In the next three years, CSPC is expected to launch more than 60 new products, of which no less than 15 blockbuster products with a market space of more than 1 billion yuan are expected
.
Data source: Mynet database, company announcements, etc.
Note: Statistics are as of March 17, if there are any omissions, please correct me!